home / stock / abus / abus quote
$2.50 Last:
4.6% Change Percent:
$2.46 Open:
$2.39 Previous Close:
$2.54 High:
$2.45 Low:
711,357 Volume:
12/31/1969 07:00:00 pm Last Trade Date Time:
Quotes are delayed by 15 to 20 minutes.
Stock Date | Open Price | Close Price | High | Low | Volume |
---|---|---|---|---|---|
2022-08-12 | 2.46 | 2.39 | 2.54 | 2.45 | 711,357 |
2022-08-11 | 2.52 | 2.39 | 2.525 | 2.44 | 784,828 |
2022-08-10 | 2.46 | 2.39 | 2.5 | 2.44 | 1,027,278 |
2022-08-09 | 2.49 | 2.39 | 2.505 | 2.4 | 927,070 |
2022-08-08 | 2.55 | 2.39 | 2.5799 | 2.465 | 984,386 |
2022-08-05 | 2.5 | 2.39 | 2.56 | 2.4508 | 966,218 |
2022-08-04 | 2.5 | 2.39 | 2.56 | 2.38 | 1,591,836 |
2022-08-03 | 2.39 | 2.39 | 2.46 | 2.25 | 2,051,433 |
2022-08-02 | 2.19 | 2.39 | 2.35 | 2.19 | 996,700 |
2022-08-01 | 2.28 | 2.39 | 2.3 | 2.2 | 728,655 |
2022-07-29 | 2.36 | 2.39 | 2.36 | 2.26 | 889,746 |
2022-07-28 | 2.39 | 2.39 | 2.39 | 2.32 | 482,363 |
2022-07-26 | 2.38 | 2.38 | 2.47 | 2.3425 | 429,774 |
2022-07-25 | 2.46 | 2.41 | 2.46 | 2.37 | 531,303 |
2022-07-19 | 2.45 | 2.51 | 2.55 | 2.45 | 711,462 |
2022-07-18 | 2.58 | 2.45 | 2.6201 | 2.43 | 755,439 |
2022-07-15 | 2.57 | 2.54 | 2.59 | 2.4505 | 525,667 |
2022-07-14 | 2.54 | 2.53 | 2.59 | 2.5 | 675,050 |
2022-07-13 | 2.53 | 2.57 | 2.67 | 2.52 | 613,899 |
2022-07-12 | 2.58 | 2.57 | 2.63 | 2.46 | 863,154 |
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
News, Short Squeeze, Breakout and More Instantly...
Image source: The Motley Fool. Arbutus Biopharma (NASDAQ: ABUS) Q2 2022 Earnings Call Aug 04, 2022 , 8:45 a.m. ET Operator Continue reading For further details see: Arbutus Biopharma (ABUS) Q2 2022 Earnings Call Transcript
Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track Financially strong with a projected cash runway into the second quarter of 2024 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Aug. 04, 2...
WARMINSTER, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled it...